Godavari Drugs Ltd (GODAVARI) is currently trading at 120.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Godavari Drugs Limited manufactures active pharmaceutical ingredients (APIs), drug intermediates and fine chemicals from its Nanded, Maharashtra facility, with Sulphamethoxazole (SMX) as the principal product and a business model that includes loan‑license manufacturing for multinational companies, multiple production blocks, and decades of operations since incorporation in 1987. The company has a clear strategic focus on capacity expansion and backward integration: SMX capacity was raised to 720 tpa, intermediate capacities for sulphamethoxide (SMO) and diethyl oxalate (DEO) have been installed, TMP capacity added, and a new API/intermediate plant is scheduled for commissioning by the end of FY2025-26 to enhance value‑addition. Recent financials show mixed performance: consolidated revenue for H1 FY26 (six months ended 30 September 2025) totaled Rs. 5,046.07 lakhs with net profit of Rs. 204.13 lakhs, reflecting a YoY decline in half‑year profitability despite sequential quarterly revenue improvement and continued pressure from high material consumption and finance costs. Market positioning remains export‑oriented around SMX demand, with product synergies from TMP and initiatives to expand Pyrazyamide and other intermediates; the company’s loan‑license model and focused product portfolio create near‑term commercial levers, while increased backward integration aims to improve margins and reduce input dependency.

Over the past 52 weeks, Godavari Drugs Ltd has traded between a low of ₹69.70 and a high of ₹144.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Godavari Drugs Ltd has a market capitalization of approximately 131.52. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Godavari Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 131.52 Cr, Godavari Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Godavari Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Godavari Drugs Ltd is 31.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Net profit was Rs 1.29 crore and net sales were Rs 33.16 crore for the quarter ended March 2026.